The bulky N(6) substituent of cabergoline is responsible for agonism of this drug at serotonin 5-HT2a and 5-HT2b receptors and thus a determinant of valvular heart disease

Kekewska A, Hübner H, Gmeiner P, Pertz HH (2011)

Publication Type: Journal article

Publication year: 2011

Journal

Journal of Pharmacology and Experimental Therapeutics American Society for Pharmacology and Experimental Therapeutics (ASPET)

Book Volume: 338

Pages Range: 381-391

DOI: 10.1124/jpet.111.181255

Authors with CRIS profile

Harald Hübner Lehrstuhl für Pharmazeutische Chemie Peter Gmeiner Lehrstuhl für Pharmazeutische Chemie

Additional Organisation(s)

Emil-Fischer-Zentrum (Emil Fischer Center)

Involved external institutions

Freie Universität Berlin DE Germany (DE)

How to cite

APA:

Kekewska, A., Hübner, H., Gmeiner, P., & Pertz, H.H. (2011). The bulky N(6) substituent of cabergoline is responsible for agonism of this drug at serotonin 5-HT2a and 5-HT2b receptors and thus a determinant of valvular heart disease. Journal of Pharmacology and Experimental Therapeutics, 338, 381-391. https://doi.org/10.1124/jpet.111.181255

MLA:

Kekewska, Alexandra, et al. "The bulky N(6) substituent of cabergoline is responsible for agonism of this drug at serotonin 5-HT2a and 5-HT2b receptors and thus a determinant of valvular heart disease." Journal of Pharmacology and Experimental Therapeutics 338 (2011): 381-391.

BibTeX: Download